# Metacrine

**Canonical:** https://apis.io/providers/metacrine/  
**APIs profiled:** 0

Metacrine, Inc. was a San Diego, California clinical-stage biopharmaceutical company founded in 2014 to develop differentiated therapies for liver and gastrointestinal disease. It built a proprietary farnesoid X receptor (FXR) platform on a distinct chemical scaffold and advanced two oral, once-daily FXR agonists — MET409 and MET642 — through Phase 1 and Phase 2 trials in non-alcoholic steatohepatitis (NASH), alongside exploratory work in inflammatory bowel disease. Backed by ARCH Venture Partners, Polaris Partners, venBio and EcoR1 Capital, it raised a $36M round in 2015 and a $65M Series C in June 2018 before pricing an initial public offering on 2020-09-15 of 6,540,000 shares at $13.00, for roughly $85.0M gross, and listing on the Nasdaq Capital Market as MTCR. Equillium, Inc. agreed to acquire the company in an all-stock transaction announced 2022-09-06, but the two mutually terminated the merger agreement on 2022-12-23. The board approved a Plan of Dissolution on 2023-01-24; Nasdaq issued a minimum-bid-price delisting notice on 2023-01-31, trading was suspended on 2023-02-09 and delisting took effect 2023-03-13; the FXR program assets were sold under a February 2023 term sheet for up to $4.0M in cash plus assumed liabilities; stockholders approved the dissolution on 2023-03-23; and the company filed a Certificate of Dissolution with the Delaware Secretary of State on 2023-03-24, effective on filing under DGCL Section 275. Metacrine was a drug developer, not a software vendor, and it never published a developer program, public API, SDK, webhook surface, or machine-readable specification of any kind. Its domain metacrine.com has since lapsed and is parked. This profile is retained as a historical record; there is no API surface to enrich.

## Kin Score — 1.8 / 100 (minimal)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 1.8).

| Facet | Score |
|---|---|
| Discoverability | 46.3 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Tags

Company, Defunct, Biotechnology, Pharmaceuticals, Life Sciences, Clinical Trials, Drug Discovery, Therapeutics, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/metacrine/). Scores are computed from the provider's own public artifacts under a published rubric.